These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38806278)

  • 21. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring autoantibodies as predictors of severe fibrosis or cirrhosis in metabolic dysfunction associated with steatotic liver disease.
    Ragheb M; Grubert Van Iderstine M; Minuk G; Faisal N
    Can Liver J; 2024 May; 7(2):291-298. PubMed ID: 38746864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD.
    Carvalho-Gontijo R; Han C; Zhang L; Zhang V; Hosseini M; Mekeel K; Schnabl B; Loomba R; Karin M; Brenner DA; Kisseleva T
    Semin Liver Dis; 2022 Aug; 42(3):233-249. PubMed ID: 36001995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Nendouvhada LP; Sibuyi NRS; Fadaka AO; Meyer S; Madiehe AM; Meyer M; Gabuza KB
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New concept in fatty liver diseases.
    Tokushige K
    Hepatol Res; 2024 Feb; 54(2):125-130. PubMed ID: 38146790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds.
    Struben VM; Hespenheide EE; Caldwell SH
    Am J Med; 2000 Jan; 108(1):9-13. PubMed ID: 11059435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
    Kanwal F; Neuschwander-Tetri BA; Loomba R; Rinella ME
    Hepatology; 2024 May; 79(5):1212-1219. PubMed ID: 38445559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two cases from the spectrum of nonalcoholic steatohepatitis.
    Abdelmalek M; Ludwig J; Lindor KD
    J Clin Gastroenterol; 1995 Mar; 20(2):127-30. PubMed ID: 7769192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
    Staufer K; Stauber RE
    Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
    Ilagan-Ying YC; Banini BA; Do A; Lam R; Lim JK
    Curr Gastroenterol Rep; 2023 Oct; 25(10):213-224. PubMed ID: 37768417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Cirrhosis Confirmed by Liver Histology after 14 Years.
    Kawanaka M; Nishino K; Morimoto Y; Ishii K; Tanikawa T; Urata N; Suehiro M; Sasai T; Haruma K; Kawamoto H
    Intern Med; 2021 May; 60(9):1397-1401. PubMed ID: 33281161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
    Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
    Clin Gastroenterol Hepatol; 2024 Sep; 22(9):1774-1789.e8. PubMed ID: 38604295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic Liver Disease and COVID-19: Alcohol Use Disorder/Alcohol-Associated Liver Disease, Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Autoimmune Liver Disease, and Compensated Cirrhosis.
    Kushner T; Cafardi J
    Clin Liver Dis (Hoboken); 2020 May; 15(5):195-199. PubMed ID: 32537135
    [No Abstract]   [Full Text] [Related]  

  • 34. Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease.
    Sanchez-Pareja A; Clément S; Peyrou M; Spahr L; Negro F; Rubbia-Brandt L; Foti M
    World J Gastroenterol; 2016 Apr; 22(14):3735-45. PubMed ID: 27076758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021.
    Enomoto H; Akuta N; Hikita H; Suda G; Inoue J; Tamaki N; Ito K; Akahane T; Kawaoka T; Morishita A; Ogawa E; Tateishi R; Yoshiji H
    Hepatol Res; 2024 Aug; 54(8):763-772. PubMed ID: 38638067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study.
    Miwa T; Tajirika S; Imamura N; Adachi M; Horita R; Hanai T; Fukao T; Shimizu M; Yamamoto M
    J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic Fatty Liver Disease vs Metabolic-associated Fatty Liver Disease vs Metabolic Dysfunction-associated Steatotic Liver Disease: What's in the Name?
    Singh SP; Sudhamshu KC; Anirvan P; Shrestha A; Mahtab MA
    Euroasian J Hepatogastroenterol; 2024; 14(1):1-4. PubMed ID: 39022204
    [No Abstract]   [Full Text] [Related]  

  • 38. In Vitro Human Liver Model of Nonalcoholic Steatohepatitis by Coculturing Hepatocytes, Endothelial Cells, and Kupffer Cells.
    Suurmond CE; Lasli S; van den Dolder FW; Ung A; Kim HJ; Bandaru P; Lee K; Cho HJ; Ahadian S; Ashammakhi N; Dokmeci MR; Lee J; Khademhosseini A
    Adv Healthc Mater; 2019 Dec; 8(24):e1901379. PubMed ID: 31746151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years.
    Powell EE; Cooksley WG; Hanson R; Searle J; Halliday JW; Powell LW
    Hepatology; 1990 Jan; 11(1):74-80. PubMed ID: 2295475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).
    Guirguis E; Dougherty J; Thornby K; Grace Y; Mack K
    Ann Pharmacother; 2024 Jun; ():10600280241259528. PubMed ID: 38887011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.